WORKATO
5.5.2021 01:03:06 CEST | Business Wire | Press release
Workato , the leading enterprise automation platform, has today launched its first EMEA data centre in Frankfurt, Germany. The new data centre has been set up in response to exceptionally strong growth in the EMEA region, the company has seen a 289% increase in data usage on its platform from EMEA in the last 12 months. The launch of the data centre is part of the company’s strategy to boost investment twofold in the region and will provide Workato customers with a centralised location for hosting their data and provide assurance that their data residency requirements including GDPR are fully compliant and that their data is secure and protected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504006038/en/
The opening of the data centre in Frankfurt is testament to the strong demand Workato is seeing from European enterprises for its integration-led automation.
Workato supports customers throughout EMEA with operations currently in Spain, UK, Germany, France, Ireland, Netherlands and Italy. In January this year, the company announced Series D funding worth $110 million to be used to invest in developing its technology and expanding product innovation to help more companies around the world transform the way they work. Workato’s current customer base comprises of companies from the tech, financial services and fintech, transport and logistics, ecommerce and retail industries and include TFG Transfracht (Deutsche Bahn Group), Box, World Economic Forum (WEF), Showpad, Jumia and WorldRemit. As part of the company’s mission to improve the way enterprises work, Workato forms strategic partnerships with organisations such as Deloitte.
Markus Zirn, SVP of Strategy & Business Development at Workato commented: “The pandemic saw digital transformation catapulted to the top priority for enterprises. With increased focus on digital strategies and remote working, EMEA enterprises quickly recognised the need for automation platforms like Workato to achieve automation at scale by easily, reliably, and securely connecting applications, data, and business processes so teams can work smarter and faster.”
He added: “In response to this very strong demand for our technology across EMEA, we have invested in this new data centre, serving our European customers to ensuring their data is held in full compliance with new EU-data regulations, eliminating any risk and allowing us to help more and more businesses within the EU transform the way they work. We are delighted to be investing in this very important region for Workato and to be expanding our operations in EMEA.”
Workato customer, Agatha Sick, Head of IT at TFG Transfracht said: "Workato is enabling us to automate workflows across our enterprise.” She continued, “We are excited about the launch of the data centre in Europe as this will provide us with the option to store our data in the EU and comply with the EU data protection regulations."
Mark Watson, Chief Technology Officer at WorldRemit , another Workato customer added: “Workato’s powerful low-code/no-code integration and automation platform is enabling us to achieve automation at scale. We are excited about the launch of Workato’s Data Center in the European Union as it will enable us to keep our data close to home.”
Workato allows companies to maximise the value of their apps, data and people by making it easy to integrate disconnected data and applications, and securely automate workflows to accelerate business outcomes. Workato’s no code/low code platform combines enterprise-grade integration and automation capabilities in a single platform that is trusted by IT and easy to use for the business. With Workato, IT and business teams can more easily collaborate to rapidly integrate data, processes, applications and user experiences in almost any combination without compromising security and governance.
About Workato
Workato is the leading Enterprise Automation Platform. Recognised as a leader, Workato is the only enterprise platform that enables both business and IT to integrate their apps, automate business workflows, and drive real time outcomes from business events, without compromising security and governance. Workato is trusted by over 7,000 of the world’s top brands and fastest growing innovators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504006038/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom